Lower Risks of New-Onset Hepatocellular Carcinoma in Patients With Type 2 Diabetes Mellitus Treated With SGLT2 Inhibitors Versus DPP4 Inhibitors
Oscar Hou In Chou(Chinese University of Hong Kong), Jiandong Zhou(City University of Hong Kong), Helen Huang(University College Hospital), Edward Christopher Dee(St Bartholomew's Hospital), Nancy Kwan Man(University of Hong Kong), Gary M. Tse(Second Hospital of Tianjin Medical University), Apichat Kaewdech(Prince of Songkla University), Ariel Ka-Man Chow(University of Hong Kong), Fengshi Jing(University of North Carolina at Chapel Hill), Tong Liu(Second Hospital of Tianjin Medical University), Jing Ning(Dalian Medical University), Raymond Chan, Cheuk To Chung, Sharen Lee, Bernard Man Yung Cheung(Chinese University of Hong Kong), Kenrick Ng(University College Hospital)
Cited by 24
Related Papers
Global Prevalence and Clinical Characteristics of Metabolic-associated Fatty Liver Disease: A Meta-Analysis and Systematic Review of 10 739 607 Individuals
|The Journal of Clinical Endocrinology & Metabolism|2022|306
Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; The APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study)
|Hepatology International|2020|295
Molecular Design Strategy to Construct the Near-Infrared Fluorescent Probe for Selectively Sensing Human Cytochrome P450 2J2
|Journal of the American Chemical Society|2018|164
The Enhanced Metastatic Potential of Hepatocellular Carcinoma (HCC) Cells with Sorafenib Resistance
|PLoS ONE|2013|124
Longitudinal Outcomes Associated With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Meta-analysis of 129 Studies
|Clinical Gastroenterology and Hepatology|2023|123